Ptc Therapeutics (PTCT) Liabilities and Shareholders Equity (2012 - 2026)

Ptc Therapeutics' Liabilities and Shareholders Equity history runs 15 years deep, the most recent figure standing at $2.9 billion for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 8.05% year-over-year to $2.9 billion in Q1 2026; TTM through Mar 2026 was $11.0 billion, a 36.05% increase from a year earlier, with the FY2025 full-year figure at $2.9 billion, up 70.01% from the prior year.
• Liabilities and Shareholders Equity eased to $2.9 billion in Q1 2026 per PTCT's latest filing, from $2.9 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $2.9 billion in Q4 2025 and bottomed at $1.3 billion in Q3 2023.
• The 5-year median for Liabilities and Shareholders Equity is $1.8 billion (2022), against an average of $2.0 billion.
• Across the five-year window, Liabilities and Shareholders Equity declined 25.83% in 2023 and soared 70.01% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $1.7 billion in 2022, then advanced by 11.14% to $1.9 billion in 2023, then declined by 10.06% to $1.7 billion in 2024, then surged by 70.01% to $2.9 billion in 2025, then fell by 1.02% to $2.9 billion in 2026.
• Per Business Quant, the three latest PTCT Liabilities and Shareholders Equity figures stand at $2.9 billion (Q1 2026), $2.9 billion (Q4 2025), and $2.6 billion (Q3 2025).